SAN RAMON, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in the Baird Healthcare Conference on Wednesday, September 13, 2023. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled to begin at 1:25 PM ET.
The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$91.88 |
| Daily Change: | -0.81 -0.87 |
| Daily Volume: | 800,737 |
| Market Cap: | US$18.340B |
December 17, 2024 December 05, 2024 September 03, 2024 August 28, 2024 August 01, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
